Argent BioPharma: A Hidden Gem traded Under $12M–Edison Group Report Assigned a $327M Valuation to Its Breakthrough Epilepsy Treatment
PERTH, Australia, Feb. 6, 2025 /PRNewswire/ — Argent BioPharma (ASX: RGT) (OTCQB: RGTLF), a clinical-stage biopharmaceutical company brings hope to epilepsy patients. For thousands of patients with refractory epilepsy—commonly referred to as drug-resistant epilepsy—the search for effective treatment often feels like navigating an endless maze. These individuals, about 30% of the epilepsy community, live with…